Baricitinib for refractory chronic graft-versus-host disease: results of a phase 1/2 study.

In 30 seconds

This phase 1/2 study evaluated the safety and efficacy of baricitinib, a JAK 1/2 inhibitor, in 24 adults with refractory chronic graft-versus-host disease (cGVHD) after hematopoietic cell transplantation. The overall response rate at 6 months was 76.2%, with median failure-free survival of 19 months, indicating promising outcomes in this challenging patient population.

Key findings

• Overall response rate at 6 months was 76.2% (95% CI, 52.8-91.8).
• Median failure-free survival was 19 months (95% CI, 11-26).
• No dose-limiting toxicities were observed at either dose level.
• Clinically meaningful improvements in patient-reported outcomes were noted.

Why it matters

Chronic graft-versus-host disease is a significant cause of morbidity and mortality in transplant survivors. Effective management options like baricitinib could improve patient outcomes and quality of life in this population.